Jonathan G Seidman

List of Publications by Year
in descending order

89	12,755	57719 44	49868 87
papers	citations	h-index	g-index

95	95	95	20622
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Integrated Genomic Characterization of Papillary Thyroid Carcinoma. Cell, 2014, 159, 676-690.	13.5	2,318
2	De novo mutations in histone-modifying genes in congenital heart disease. Nature, 2013, 498, 220-223.	13.7	798
3	Macrophages Facilitate Electrical Conduction in the Heart. Cell, 2017, 169, 510-522.e20.	13.5	703
4	De novo mutations in congenital heart disease with neurodevelopmental and other congenital anomalies. Science, 2015, 350, 1262-1266.	6.0	646
5	Contribution of rare inherited and de novo variants in 2,871 congenital heart disease probands. Nature Genetics, 2017, 49, 1593-1601.	9.4	624
6	IL-11 is a crucial determinant of cardiovascular fibrosis. Nature, 2017, 552, 110-115.	13.7	451
7	A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations. Cancer Cell, 2017, 31, 820-832.e3.	7.7	433
8	Shared Genetic Predisposition in Peripartum and Dilated Cardiomyopathies. New England Journal of Medicine, 2016, 374, 233-241.	13.9	432
9	The Translational Landscape of the Human Heart. Cell, 2019, 178, 242-260.e29.	13.5	407
10	Integrated allelic, transcriptional, and phenomic dissection of the cardiac effects of titin truncations in health and disease. Science Translational Medicine, 2015, 7, 270ra6.	5.8	375
11	De novo copy number variants identify new genes and loci in isolated sporadic tetralogy of Fallot. Nature Genetics, 2009, 41, 931-935.	9.4	373
12	Cardiac fibrosis in mice with hypertrophic cardiomyopathy is mediated by non-myocyte proliferation and requires Tgf-Î². Journal of Clinical Investigation, 2010, 120, 3520-3529.	3.9	372
13	Cardiac-Specific YAP Activation Improves Cardiac Function and Survival in an Experimental Murine MI Model. Circulation Research, 2014, 115, 354-363.	2.0	324
14	Titin-truncating variants affect heart function in disease cohorts and the general population. Nature Genetics, 2017, 49, 46-53.	9.4	255
15	Deciphering the super relaxed state of human Î²-cardiac myosin and the mode of action of mavacamten from myosin molecules to muscle fibers. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E8143-E8152.	3.3	248
16	Clinical and Mechanistic Insights Into theÂGenetics of Cardiomyopathy. Journal of the American College of Cardiology, 2016, 68, 2871-2886.	1.2	244
17	Increased Frequency of De Novo Copy Number Variants in Congenital Heart Disease by Integrative Analysis of Single Nucleotide Polymorphism Array and Exome Sequence Data. Circulation Research, 2014, 115, 884-896.	2.0	229
18	Genetic Variants Associated With Cancer Therapyâ€“Induced Cardiomyopathy. Circulation, 2019, 140, 31-41.	1.6	195

#	Article	IF	Citations
19	A Tension-Based Model Distinguishes Hypertrophic versus Dilated Cardiomyopathy. Cell, 2016, 165, 1147-1159.	13.5	193
20	Myosin Sequestration Regulates Sarcomere Function, Cardiomyocyte Energetics, and Metabolism, Informing the Pathogenesis of Hypertrophic Cardiomyopathy. Circulation, 2020, 141, 828-842.	1.6	181
21	Spatiotemporal Multi-Omics Mapping Generates a Molecular Atlas of the Aortic Valve and Reveals Networks Driving Disease. Circulation, 2018, 138, 377-393.	1.6	180
22	Effects of myosin variants on interacting-heads motif explain distinct hypertrophic and dilated cardiomyopathy phenotypes. ELife, 2017, 6, .	2.8	153
23	Hypertrophic cardiomyopathy mutations in MYBPC3 dysregulate myosin. Science Translational Medicine, 2019, 11, .	5.8	133
24	Targeted and genome-wide sequencing reveal single nucleotide variations impacting specificity of Cas9 in human stem cells. Nature Communications, 2014, 5, 5507.	5.8	128
25	Force Generation via Î²-Cardiac Myosin, Titin, and Î±-Actinin Drives Cardiac Sarcomere Assembly from Cell-Matrix Adhesions. Developmental Cell, 2018, 44, 87-96.e5.	3.1	120
26	Genetics of hypertrophic cardiomyopathy. Current Opinion in Cardiology, 2010, 25, 205-209.	0.8	112
27	Advances in the Genetic Basis and Pathogenesis of Sarcomere Cardiomyopathies. Annual Review of Genomics and Human Genetics, 2019, 20, 129-153.	2.5	108
28	Genomic analyses implicate noncoding de novo variants in congenital heart disease. Nature Genetics, 2020, 52, 769-777.	9.4	97
29	Activin type II receptor signaling in cardiac aging and heart failure. Science Translational Medicine, 2019, 11, .	5.8	95
30	SarcTrack. Circulation Research, 2019, 124, 1172-1183.	2.0	94
31	Genomic frontiers in congenital heart disease. Nature Reviews Cardiology, 2022, 19, 26-42.	6.1	93
32	Molecular profiling of dilated cardiomyopathy that progresses to heart failure. JCI Insight, 2016, 1, .	2.3	85
33	Genetic Pathogenesis of Hypertrophic and Dilated Cardiomyopathy. Heart Failure Clinics, 2018, 14, 139-146.	1.0	83
34	Integrative Analysis of PRKAG2 Cardiomyopathy iPS and Microtissue Models Identifies AMPK as a Regulator of Metabolism, Survival, and Fibrosis. Cell Reports, 2016, 17, 3292-3304.	2.9	73
35	A Pan-Cancer Compendium of Genes Deregulated by Somatic Genomic Rearrangement across More Than 1,400 Cases. Cell Reports, 2018, 24, 515-527.	2.9	70
36	Hierarchical and stage-specific regulation of murine cardiomyocyte maturation by serum response factor. Nature Communications, 2018, 9, 3837.	5.8	63

#	Article	IF	Citations
37	Paternal-age-related de novo mutations and risk for five disorders. Nature Communications, 2019, 10, 3043.	5.8	63
38	Nationwide Study on Hypertrophic Cardiomyopathy in Iceland. Circulation, 2014, 130, 1158-1167.	1.6	62
39	Haploinsufficiency of MYBPC3 exacerbates the development of hypertrophic cardiomyopathy in heterozygous mice. Journal of Molecular and Cellular Cardiology, 2015, 79, 234-243.	0.9	58
40	Association of Variants in BAG3 With Cardiomyopathy Outcomes in African American Individuals. JAMA Cardiology, 2018, 3, 929.	3.0	57
41	Aggregate penetrance of genomic variants for actionable disorders in European and African Americans. Science Translational Medicine, 2016, 8, 364ra151.	5.8	55
42	Phenotype and prognostic correlations of the converter region mutations affecting the Î² myosin heavy chain. Heart, 2015, 101, 1047-1053.	1.2	54
43	RNA expression profile of calcified bicuspid, tricuspid, and normal human aortic valves by RNA sequencing. Physiological Genomics, 2016, 48, 749-761.	1.0	52
44	Telomere shortening is a hallmark of genetic cardiomyopathies. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 9276-9281.	3.3	51
45	UBQLN2 mutation causing heterogeneous Xâ€linked dominant neurodegeneration. Annals of Neurology, 2014, 75, 793-798.	2.8	50
46	Marked Up-Regulation of ACE2 in Hearts of Patients With Obstructive Hypertrophic Cardiomyopathy: Implications for SARS-CoV-2â€“Mediated COVID-19. Mayo Clinic Proceedings, 2020, 95, 1354-1368.	1.4	49
47	Genetics and Disease of Ventricular Muscle. Cold Spring Harbor Perspectives in Medicine, 2014, 4, a021063-a021063.	2.9	47
48	Novel Therapies for Prevention and Early Treatment of Cardiomyopathies. Circulation Research, 2019, 124, 1536-1550.	2.0	47
49	Global impact of somatic structural variation on the DNA methylome of human cancers. Genome Biology, 2019, 20, 209.	3.8	40
50	Yin Yang 1 Suppresses Dilated Cardiomyopathy and Cardiac Fibrosis Through Regulation of Bmp7 and Ctgf. Circulation Research, 2019, 125, 834-846.	2.0	34
51	Small-Molecule Screen Identifies De Novo Nucleotide Synthesis as a Vulnerability of Cells Lacking SIRT3. Cell Reports, 2018, 22, 1945-1955.	2.9	31
52	CalTrack: High-Throughput Automated Calcium Transient Analysis in Cardiomyocytes. Circulation Research, 2021, 129, 326-341.	2.0	31
53	GATA6 mutations in hiPSCs inform mechanisms for maldevelopment of the heart, pancreas, and diaphragm. ELife, 2020, 9, .	2.8	31
54	De Novo Damaging Variants, Clinical Phenotypes, and Post-Operative Outcomes in Congenital Heart Disease. Circulation Genomic and Precision Medicine, 2020, 13, e002836.	1.6	30

#	Article	IF	Citations
55	Engineering a living cardiac pump on a chip using high-precision fabrication. Science Advances, 2022, 8, eabm3791.	4.7	30
56	Rare genetic variation at transcription factor binding sites modulates local DNA methylation profiles. PLoS Genetics, 2020, 16, e1009189.	1.5	27
57	ViroFind: A novel target-enrichment deep-sequencing platform reveals a complex JC virus population in the brain of PML patients. PLoS ONE, 2018, 13, e0186945.	1.1	25
58	Filamin C Cardiomyopathy Variants Cause Protein and Lysosome Accumulation. Circulation Research, 2021, 129, 751-766.	2.0	25
59	BET bromodomain proteins regulate transcriptional reprogramming in genetic dilated cardiomyopathy. JCI Insight, 2020, 5, .	2.3	23
60	Alpha blockade potentiates CPVT therapy in calsequestrin-mutant mice. Heart Rhythm, 2014, 11, 1471-1479.	0.3	22
61	Myocardial Iron Deficiency and Mitochondrial Dysfunction in Advanced Heart Failure in Humans. Journal of the American Heart Association, 2022, 11, .	1.6	22
62	Discordant clinical features of identical hypertrophic cardiomyopathy twins. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	19
63	Detection of Cell Proliferation Markers by Immunofluorescence Staining and Microscopy Imaging in Paraffinâ€Embedded Tissue Sections. Current Protocols in Molecular Biology, 2016, 115, 14.25.1-14.25.14.	2.9	18
64	Genetic Studies of Hypertrophic Cardiomyopathy in Singaporeans Identify Variants in TNNI3 and TNNT2 That Are Common in Chinese Patients. Circulation Genomic and Precision Medicine, 2020, 13, 424-434.	1.6	18
65	Fabry Disease in Families With Hypertrophic Cardiomyopathy. Circulation: Cardiovascular Genetics, 2017, 10, .	5.1	17
66	Contribution of Noncanonical Splice Variants toTTNTruncating Variant Cardiomyopathy. Circulation Genomic and Precision Medicine, 2021, 14, e003389.	1.6	15
67	The Role of the L-Type Ca2+ Channel in Altered Metabolic Activity in a Murine Model of Hypertrophic Cardiomyopathy. JACC Basic To Translational Science, 2016, 1, 61-72.	1.9	12
68	Plakophilin-2 truncating variants impair cardiac contractility by disrupting sarcomere stability and organization. Science Advances, 2021, 7, eabh3995.	4.7	11
69	Hypertrophic cardiomyopathy in myosin-binding protein C (MYBPC3) Icelandic founder mutation carriers. Open Heart, 2020, 7, e001220.	0.9	10
70	Genetics of cancer therapy-associated cardiotoxicity. Journal of Molecular and Cellular Cardiology, 2022, 167, 85-91.	0.9	10
71	Cell cycle defects underlie childhood-onset cardiomyopathy associated with Noonan syndrome. IScience, 2022, 25, 103596.	1.9	9
72	A functional genomic approach to actionable gene fusions for precision oncology. Science Advances, 2022, 8, eabm2382.	4.7	9

#	Article	IF	Citations
73	Preparation of rAAV9 to Overexpress or Knockdown Genes in Mouse Hearts. Journal of Visualized Experiments, 2016, , .	0.2	8
74	A Novel Role for CSRP1 in a Lebanese Family with Congenital Cardiac Defects. Frontiers in Genetics, 2017, 8, 217.	1.1	8
75	Genetic profiling of fatty acid desaturase polymorphisms identifies patients who may benefit from high-dose omega-3 fatty acids in cardiac remodeling after acute myocardial infarctionâ€"Post-hoc analysis from the OMEGA-REMODEL randomized controlled trial. PLoS ONE, 2019, 14, e0222061.	1.1	8
76	Congenital Heart Defects Due to TAF1 Missense Variants. Circulation Genomic and Precision Medicine, 2020, 13, e002843.	1.6	8
77	Genome-Wide De Novo Variants in Congenital Heart Disease Are Not Associated With Maternal Diabetes or Obesity. Circulation Genomic and Precision Medicine, 2022, 15, CIRCGEN121003500.	1.6	8
78	Early remodeling of repolarizing K+ currents in the Î±MHC403/+ mouse model of familial hypertrophic cardiomyopathy. Journal of Molecular and Cellular Cardiology, 2017, 103, 93-101.	0.9	7
79	Founder Mutation in N Terminus of Cardiac Troponin I Causes Malignant Hypertrophic Cardiomyopathy. Circulation Genomic and Precision Medicine, 2020, 13, 444-452.	1.6	7
80	Probing the subcellular nanostructure of engineered human cardiomyocytes in 3D tissue. Microsystems and Nanoengineering, 2021, 7, 10.	3.4	7
81	Cardiomyocyte Proliferative Capacity Is Restricted in Mice With Lmna Mutation. Frontiers in Cardiovascular Medicine, 2021, 8, 639148.	1.1	7
82	The Muscle-Bound Heart. Cardiac Electrophysiology Clinics, 2016, 8, 223-231.	0.7	6
83	Population Prevalence of Premature Truncating Variants in Plakophilin-2 and Association With Arrhythmogenic Right Ventricular Cardiomyopathy: A UK Biobank Analysis. Circulation Genomic and Precision Medicine, 2022, 15, 101161CIRCGEN121003507.	1.6	5
84	Novel and Annotated Long Noncoding RNAs Associated with Ischemia in the Human Heart. International Journal of Molecular Sciences, 2021, 22, 11324.	1.8	4
85	An ancient founder mutation located betweenROBO1andROBO2is responsible for increased microtia risk in Amerindigenous populations. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2203928119.	3.3	4
86	Robust identification of deletions in exome and genome sequence data based on clustering of Mendelian errors. Human Mutation, 2018, 39, 870-881.	1.1	3
87	Abstract 402: Defining Diverse Disease Pathomechanisms Across Thick And Thin Filament Hypertrophic Cardiomyopathy Variants.. Circulation Research, 2021, 129, .	2.0	3
88	Abstract 188: Sarcomere Protein Cardiac Myosin Binding Protein C Regulates Cardiomyocyte Proliferation. Circulation Research, 2013, 113, .	2.0	0
89	Demystifying Cardiac Iron Deficiency in Endâ€stage Heart Failure. FASEB Journal, 2022, 36, .	0.2	0